東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ subject:"Drugs- Side effects." ]

切換: 標籤 | MARC模式 | ISBD

Pharmacovigilance = critique and way...

Edwards, I. Ralph.

FindBook

Google Book

Amazon

博客來

Pharmacovigilance = critique and ways forward /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Pharmacovigilance/ edited by I. Ralph Edwards, Marie Lindquist.
其他題名:	critique and ways forward /
其他作者:	Edwards, I. Ralph.
出版者:	Cham :Springer International Publishing : : 2017.,
面頁冊數:	xxxi, 205 p. :ill., digital ;24 cm.
內容註:	1. How to learn Pharmacovigilance, now and in the Future -- 2. Lost in Regulation -- 3. What is the Future of Pharmacovigilance and how can we Make it as Good as Possible? -- 4. Some Other Ideas About the Future of Pharmacovigilance -- 5. Best Safety Practices now and in the Future -- 6. Is There a Benefit from the Medical Literature Monitoring Service of the EMA? -- 7. The Unified Drug Safety-Clinical Database -- 8. Behind the Scenes - 'Silent Factors' Influencing Pharmacovigilance Practice and Decisions -- 9. Shaking up Culture and Communication in PV [V6] -- 10. Broadening the Scope of Pharmacovigilance -- 11. Effective Treatment Matters: Revitalizing Pharmacoviglance -- 12. There are More Weber-Effects -- 13. Herbal and Traditional Medicines, Now and Future -- 14. The Concept of 'Health' -- 15. Impact of Referral Procedures on the Interaction of RMP and PSUR -- 16. Other Sources of Information for Monitoring Drug Safety: Now and in the Future -- 17. Ecopharmacovigilance.
Contained By:	Springer eBooks
標題:	Pharmacoepidemiology. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-40400-4
ISBN:	9783319404004

Pharmacovigilance = critique and ways forward /
Pharmacovigilancecritique and ways forward /[electronic resource] :edited by I. Ralph Edwards, Marie Lindquist. - Cham :Springer International Publishing :2017. - xxxi, 205 p. :ill., digital ;24 cm.

1. How to learn Pharmacovigilance, now and in the Future -- 2. Lost in Regulation -- 3. What is the Future of Pharmacovigilance and how can we Make it as Good as Possible? -- 4. Some Other Ideas About the Future of Pharmacovigilance -- 5. Best Safety Practices now and in the Future -- 6. Is There a Benefit from the Medical Literature Monitoring Service of the EMA? -- 7. The Unified Drug Safety-Clinical Database -- 8. Behind the Scenes - 'Silent Factors' Influencing Pharmacovigilance Practice and Decisions -- 9. Shaking up Culture and Communication in PV [V6] -- 10. Broadening the Scope of Pharmacovigilance -- 11. Effective Treatment Matters: Revitalizing Pharmacoviglance -- 12. There are More Weber-Effects -- 13. Herbal and Traditional Medicines, Now and Future -- 14. The Concept of 'Health' -- 15. Impact of Referral Procedures on the Interaction of RMP and PSUR -- 16. Other Sources of Information for Monitoring Drug Safety: Now and in the Future -- 17. Ecopharmacovigilance.

Written by experienced authors, this book offers expert personal views on what the current problems in pharmacovigilance are and how they should be solved. This book stems from thoughts and ideas discussed in a series of meetings of the International Society of Pharmacovigilance (ISoP), where concerns were raised that the current pharmacovigilance system is not delivering optimally to improve therapeutics in clinical practice. Pharmacovigilance of the future must be an active and integral part of health care delivery, and focus more on science and practices that support health professionals and patients in day-to-day care situations. To achieve this, a dynamic and sustainable development of vigilance must take precedence over the current excessive preoccupations with data processing and regulations; all aspects of medicines use and their effects need to be considered; and all stakeholders must be involved and engaged in an open and constructive debate. The work is essential reading for anyone who has an interest in safer use of medicines. It is intended to be equally challenging and rewarding, and sets out to stimulate a continuous debate on how pharmacovigilance can better meet the needs of health professionals and patients to achieve the aim of wise therapeutic decision making.

ISBN: 9783319404004

Standard No.: 10.1007/978-3-319-40400-4doiSubjects--Topical Terms:

2181432
Pharmacoepidemiology.

LC Class. No.: RM302.5

Dewey Class. No.: 615.7045

Pharmacovigilance = critique and ways forward /
LDR:03227nmm a2200313 a 4500 001 2088221
003 DE-He213
005 20161028155316.0
006 m d
007 cr nn 008maaau
008 171013s2017 gw s 0 eng d
020 $a 9783319404004 $q (electronic bk.)
020 $a 9783319403991 $q (paper)
024 7 $a 10.1007/978-3-319-40400-4 $2 doi
035 $a 978-3-319-40400-4
040 $a GP $c GP
041 0 $a eng
050 4 $a RM302.5
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 615.7045 $2 23
090 $a RM302.5 $b .P536 2017
245 0 0 $a Pharmacovigilance $h [electronic resource] : $b critique and ways forward / $c edited by I. Ralph Edwards, Marie Lindquist.
260 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2017.
300 $a xxxi, 205 p. : $b ill., digital ; $c 24 cm.
505 0 $a 1. How to learn Pharmacovigilance, now and in the Future -- 2. Lost in Regulation -- 3. What is the Future of Pharmacovigilance and how can we Make it as Good as Possible? -- 4. Some Other Ideas About the Future of Pharmacovigilance -- 5. Best Safety Practices now and in the Future -- 6. Is There a Benefit from the Medical Literature Monitoring Service of the EMA? -- 7. The Unified Drug Safety-Clinical Database -- 8. Behind the Scenes - 'Silent Factors' Influencing Pharmacovigilance Practice and Decisions -- 9. Shaking up Culture and Communication in PV [V6] -- 10. Broadening the Scope of Pharmacovigilance -- 11. Effective Treatment Matters: Revitalizing Pharmacoviglance -- 12. There are More Weber-Effects -- 13. Herbal and Traditional Medicines, Now and Future -- 14. The Concept of 'Health' -- 15. Impact of Referral Procedures on the Interaction of RMP and PSUR -- 16. Other Sources of Information for Monitoring Drug Safety: Now and in the Future -- 17. Ecopharmacovigilance.
520 $a Written by experienced authors, this book offers expert personal views on what the current problems in pharmacovigilance are and how they should be solved. This book stems from thoughts and ideas discussed in a series of meetings of the International Society of Pharmacovigilance (ISoP), where concerns were raised that the current pharmacovigilance system is not delivering optimally to improve therapeutics in clinical practice. Pharmacovigilance of the future must be an active and integral part of health care delivery, and focus more on science and practices that support health professionals and patients in day-to-day care situations. To achieve this, a dynamic and sustainable development of vigilance must take precedence over the current excessive preoccupations with data processing and regulations; all aspects of medicines use and their effects need to be considered; and all stakeholders must be involved and engaged in an open and constructive debate. The work is essential reading for anyone who has an interest in safer use of medicines. It is intended to be equally challenging and rewarding, and sets out to stimulate a continuous debate on how pharmacovigilance can better meet the needs of health professionals and patients to achieve the aim of wise therapeutic decision making.
650 0 $a Pharmacoepidemiology. $3 2181432
650 0 $a Drugs $x Side effects. $3 789547
650 0 $a Drug interactions. $3 548667
650 1 4 $a Medicine & Public Health. $3 890906
650 2 4 $a Drug Safety and Pharmacovigilance. $3 2108855
700 1 $a Edwards, I. Ralph. $3 1581970
700 1 $a Lindquist, Marie. $3 3217807
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-40400-4
950 $a Medicine (Springer-11650)